Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;26(12):1616-1617.
doi: 10.18553/jmcp.2020.26.12.1616.

A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"

Sarika Ogale  1 , Clarissa Emy Higuchi Zerbini  2 , Miranta Antoniou  2 , Romain Freund  2
Affiliations
Comment

A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"

Sarika Ogale et al. J Manag Care Spec Pharm. 2020 Dec.

Abstract

DISCLOSURES: The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc.

PubMed Disclaimer

Conflict of interest statement

The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc.

Comment in

  • THE AUTHORS RESPOND.
    Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD. Roth JA, et al. J Manag Care Spec Pharm. 2020 Dec;26(12):1617-1618. doi: 10.18553/jmcp.2020.26.12.1617. J Manag Care Spec Pharm. 2020. PMID: 33251990 Free PMC article.

Comment on

References

    1. Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD. The potential long-term comparative effectiveness of larotrectinib and entrectinib for second-line treatment of TRK fusion-positive metastatic lung cancer. J Manag Care Spec Pharm. 2020;26(8):981-86. doi: 10.18553/jmcp.2020.20045 - PMC - PubMed
    1. Hyman DM, van Tilburg CM, Albert CM, et al. . Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol. 2019;30(Suppl 5):v159-93 (Abstract 445PD).
    1. Paz-Ares L, Doebele RC, Farago AF, et al. . Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 2019;30(Suppl. 2):ii48-49 (Abstract 113O).
    1. Hoaglin DC, Hawkins N, Jansen JP, et al. . Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429-37. - PubMed
    1. Chu P, Batson S, Hodgson M, Mitchell CR, Steenrod A. Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy. Future Oncol. 2020;16(4):61-74. - PubMed